NCT03855202|UnknownPhase 1
The Treatment of Bronchopulmonary Dysplasia by Instillation PS and Mononuclaer Cells in Preterms
BPD
Loading search results
BPD
Sponsor study identifier
interventional
320
0 countries
N/A
Study Start
February 24, 2019
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
August 1, 2019
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
August 20, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Bronchopulmonary dysplasia mainly occurs in premature infants, which is the main cause of premature infant death.If children with BPD can survive, they are also prone to complications of long-term respiratory diseases such as asthma,that affect the quality of life of BPD children. However, there is no effective treatment method for BPD. So,the investigator would like to investigate the effect of Intratracheal PS and mononuclaer cells in pretems
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 20, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 24, 2019
Actual (reported)February 24, 2019
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
February 26, 2019
Actual (reported)August 1, 2019
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
August 20, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
number of patients who died
mority rate
up to 21 days after birth
number of patients with neurodevelopmental disorder assessed by Bayley Score
up to 1 month, 3 month, 6 months and 1 year
autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg
autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg
PS,dose is 70mg/kg
autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg
autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg
Jie Yang, PHD
Guangdong Women and Children Hospital
First Submitted
February 24, 2019
First Posted
February 26, 2019
Study Start
February 24, 2019
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
0.9% sodium chloride installation after 24 hours
PS,dose is 70mg/kg
0.9% sodium chloride installation after 24 hours
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
August 1, 2019
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
August 20, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
February 26, 2019
Record last verified: 2019-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: